Clincial Study Patient Recruitment and Site Engagement

Muscle-Invasive Bladder Cancer

Stark Raving Branding and Digital Marketing

Helping to Build a Plan – Post-Cystectomy



IndicationBladder Cancer


 Patient Education

 Site Staff Materials

 Referring Physician

 Patient Retention

IMvigor010 was the first randomized Phase III study of TECENTRIQ compared to chemotherapy in people with advanced bladder cancer who were previously treated with a platinum-based chemotherapy. The study evaluated the efficacy and safety of TECENTRIQ compared to chemotherapy (vinflunine, paclitaxel or docetaxel) administered every three weeks in people with previously-treated mUC who progressed during or following a platinum-based regimen.

Eligible patients had an Eastern Cooperative Oncology Group performance status of 0-1, an evaluable tumor sample for centralised PD-L1 testing and had received at least one prior therapeutic regimens for mUC or who had developed mUC within 12 months of receiving platinum-based chemotherapy before surgery (neoadjuvant) or after surgery (adjuvant). The primary efficacy endpoint was OS and key secondary endpoints include objective response rate, progression-free survival, duration of response and safety.
Data Sheet Design

White Paper Design

White Paper Detail

Stark Raving Branding and Digital Marketing

Let's talk about your next project
To discuss an upcoming project or to learn more about our services, please contact us.

Be sure you complete all fields. Thank you!